Loading…
Anixa Biosciences is a clinical-stage biotechnology company developing therapies and vaccines to treat and prevent cancer. Its pipeline includes a CAR-T therapy for ovarian cancer (lira-cel), developed in collaboration with the Wistar Institute and Moffitt Cancer Center, and a vaccine for the treatment and prevention of breast cancer developed in collaboration with Cleveland Clinic.
NASDAQ: ANIX
Anixa is building a diversified immuno-oncology pipeline that attacks cancer from two directions — treatment and prevention — alongside some of the most respected organizations in cancer research and treatment.
Its therapeutic program centers on a CAR-T therapy targeting the follicle-stimulating hormone receptor (FSHR) in ovarian cancer, a disease with few durable treatment options, licensed from the Wistar Institute and advanced in collaboration with Moffitt Cancer Center.
The Company’s alpha-lactalbumin vaccine—developed with Cleveland Clinic and supported by funding from the US Department of Defense—is designed to treat existing cancer as well as to reduce the chance it returns or develops in the first place.
An FSHR-targeted CAR-T therapy for ovarian cancer and an alpha-lactalbumin vaccine to treat and prevent breast cancer.
Cleveland Clinic, Moffitt Cancer Center, the National Cancer Institute, the U.S. Department of Defense, and The Wistar Institute.
A strategy pursuing multiple "shots on goal" targeting unmet medical needs and very large domestic and international markets.
This vaccine utilizes a molecular mechanism that has never been utilized before and has the potential to prevent most, if not all, breast cancers.
Institutional partnerships let Anixa advance several programs without shouldering the full cost of each alone.
Growing international patent protection for all of its programs
Oct 01, 2026 · 8:45 AM EDT
The second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The study is being conducted at Moffitt Cancer Center ("Moffitt").
The company's insiders have been consistent buyers of company stock. See a list of insider transactions here.
Get press releases, SEC filings and event alerts delivered to your inbox.
